COMPARACIONES Y RESULTADOS CLINICOS EN EL CANCER DE MAMA: TAMOXIFENO E INHIBIDORES DE LA AROMATASA ADYUVANTES
Columnista Experta de SIIC J. Michael Dixon
en colaboración con
E. Jane Macaskill , MBChB, MRCS. Edinburgh Breast Unit, Western General Hospital; Juliette Jackson , MBChB, MRCS. Edinburgh Breast Unit, Western General Hospital; Lorna Renshaw , RGN. Edinburgh Breast Unit, Western General Hospital; William R. Miller , BSc, PhD, DSc. Edinburgh Breast Unit, Western General Hospital
Fecha de aprobación: 17 de enero, 2005
Primera edición en siicsalud:
24 de noviembre, 2005
Sección Artículos originales,
subsección
Expertos de Iberoamérica,
página
/des/expertocompleto.php/71974
Especialidad principal:
Oncología
Especialidades relacionadas:
Farmacología,Medicina Farmacéutica,Medicina Familiar,Medicina Interna,Obstetricia y Ginecología,
Dixon JM. Exemestane and aromatase inhibitors in the management of advanced breast cancer, Expert Opinion on Pharmacotherapy 5:307-316
Barber MD, Jack W, Dixon JM. Diagnostic delay in breast cancer, British Journal of Surgery 91:49-53
Gaston MS, Dixon JM. A survey of surgical management of the axilla in UK breast cancer patients, European Journal of Cancer 40:1738-1742
Somner JEA, Dixon JM, Thomas St J. Node retrieval in axillary lymph node dissections: recommendations for minimum numbers to be confident about node-negative status, Journal of Clinical Pathology 57:845-848
Dixon JM, Young OE. Neoadjuvant exemestane in the treatment of invasive breast carcinoma in postmenopausal women, Case Studies in Breast Cancer 3:
Hayward RL, Dixon JM. Current limits of knowledge in adjuvant and neoadjuvant endocrine therapy of breast cancer: the need for more clinical research, Surgical Oncology 12:289-304
J. Michael Dixon
